Skip to content
Menu

B. Riley Securities Reiterates Buy on Orchestra BioMed Hldgs, Raises Price Target to $12

Benzinga Newsdesk 2 days ago

Analyst RatingsNewsReiterationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

B. Riley Securities analyst Madison El-Saadi reiterates Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and raises the price target from $11 to $12.

B. Riley Securities analyst Madison El-Saadi reiterates Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and raises the price target from $11 to $12.

Read at benzinga.com

← All stock news